Author(s): Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A,
Abstract Share this page
Abstract 3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1. TRIAL REGISTRATION: ClinicalTrials.gov NCT02018510. Copyright © 2016, American Association for the Advancement of Science.
This article was published in Science
and referenced in HIV: Current Research